OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Harshman Discusses the Potential for New RCC Treatments

May 10th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Dr. Chase on the Standard of Care for Uterine Leiomyosarcoma

May 9th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 9th 2018

Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL

May 9th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Dr. Wistinghausen Discusses the Treatment of Pediatric NHL

May 9th 2018

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses the treatment of pediatric patients with non-Hodgkin lymphoma.

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian Cancer

May 9th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses a study on the effects of long-term bevacizumab (Avastin) use in patients with ovarian cancer.

Dr. Goy Discusses the Evolution of Treatment for MCL

May 9th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr. Mark on the Use of Degarelix in Men With Prostate Cancer

May 8th 2018

James Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.

Dr. Godwin on Ongoing Clinical Trials for Men With Prostate Cancer

May 8th 2018

James L. Godwin, MD, physician, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses ongoing trials for men with prostate cancer.

Dr. Rivera on the National Lung Screening Trial

May 8th 2018

M. Patricia Rivera, MD, professor of medicine, UNC Chapel Hill, UNC Lineberger Comprehensive Cancer Center, discusses novel methods of detecting high-risk lung cancer.

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

May 8th 2018

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.

Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

May 8th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

Dr. Verma Discusses Challenges With Biosimilars in Oncology

May 8th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses challenges with integrating biosimilars into practice.

Dr. Berdeja on FDA Approval of Frontline Daratumumab Plus VMP in Multiple Myeloma

May 8th 2018

Jesus G. Berdeja, MD, director of Myeloma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of frontline daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

Dr. Bergsagel on Treatment Options for Relapsed/Refractory Myeloma

May 7th 2018

Leif Bergsagel, MD, consultant and professor of medicine, Division of Hematology/Oncology, Mayo Clinic, discusses treatment options for patients with relapsed/refractory multiple myeloma.

Dr. Trabulsi Defines Locally Advanced Prostate Cancer

May 7th 2018

Edouard J. Trabulsi, MD, FACS, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, defines locally advanced prostate cancer.

Dr. Skarbnik Discusses the Changing Landscape of CLL

May 7th 2018

Alan Skarbnik, MD, staff physician, Department of Bone Marrow Transplantation and Department of Lymphoma, John Theurer Cancer Center, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 7th 2018

Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS

May 7th 2018

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

Dr. Ghosh on the Future of CAR T-Cell Therapy in Patients With Hematologic Malignancies

May 7th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with hematologic malignancies.